CARPROFEN tablet, chewable

Country: United States

Language: English

Source: NLM (National Library of Medicine)

Active ingredient:

CARPROFEN (UNII: FFL0D546HO) (CARPROFEN - UNII:FFL0D546HO)

Available from:

BUTLER ANIMAL HEALTH SUPPLY, LLC DBA COVETRUS NORTH AMERICA

Administration route:

ORAL

Prescription type:

PRESCRIPTION

Therapeutic indications:

Carprofen Chewable Tablets are indicated for the relief of pain and inflammation associated with osteoarthritis and for the control of postoperative pain associated with soft tissue and orthopedic surgeries in dogs. Carprofen Chewable Tablets should not be used in dogs exhibiting previous hypersensitivity to carprofen.

Product summary:

Carprofen Chewable Tablets are scored, and contain 25 mg, 75 mg, or 100 mg of carprofen per tablet. Each tablet size is packaged in bottles containing 30, 60, or 180 tablets.

Authorization status:

Abbreviated New Animal Drug Application

Summary of Product characteristics

CARPROFEN - CARPROFEN TABLET, CHEWABLE
BUTLER ANIMAL HEALTH SUPPLY, LLC DBA COVETRUS NORTH AMERICA
----------
CARPROFEN
CHEWABLE TABLETS
CARPROFEN
CHEWABLE TABLETS
_NON-STEROIDAL ANTI-INFLAMMATORY DRUG_
FOR ORAL USE IN DOGS ONLY
CAUTION:
Federal law restricts this drug to use by or on the order of a
licensed veterinarian.
DESCRIPTION:
Carprofen Chewable Tablets are a non-steroidal anti-inflammatory drug
(NSAID) of the
propionic acid class that includes ibuprofen, naproxen, and
ketoprofen. Carprofen is the
nonproprietary designation for a substituted carbazole,
6-chloro-α-methyl-9_H_-carbazole-
2-acetic acid. The empirical formula is C
H
ClNO and the molecular weight 273.72.
The chemical structure of carprofen is:
Carprofen is a white, crystalline compound. It is freely soluble in
ethanol, but practically
insoluble in water at 25°C.
CLINICAL PHARMACOLOGY:
Carprofen is a non-narcotic, non-steroidal anti-inflammatory agent
with characteristic
analgesic and antipyretic activity approximately equipotent to
indomethacin in animal
models.
The mechanism of action of carprofen, like that of other NSAIDs, is
believed to be
associated with the inhibition of cyclooxygenase activity. Two unique
cyclooxygenases
have been described in mammals.
The constitutive cyclooxygenase, COX-1,
synthesizes prostaglandins necessary for normal gastrointestinal and
renal function.
15
12
2
1
2
The inducible cyclooxygenase, COX-2, generates prostaglandins involved
in
inflammation. Inhibition of COX-1 is thought to be associated with
gastrointestinal and
renal toxicity while inhibition of COX-2 provides anti-inflammatory
activity. The specificity
of a particular NSAID for COX-2 versus COX-1 may vary from species to
species.
In an
_in vitro_ study using canine cell cultures, carprofen demonstrated
selective inhibition of
COX-2 versus COX-1.
Clinical relevance of these data has not been shown. Carprofen
has also been shown to inhibit the release of several prostaglandins
in two inflammatory
cell systems: rat polymorphonuclear leukocytes (PMN) an